Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.65 |
| ▸ | MMP2 | P08253 | 8/20 | 0.48 |
| ▸ | MMP3 | P08254 | 8/20 | 0.48 |
| ▸ | MMP7 | P09237 | 6/20 | 0.48 |
| ▸ | MMP1 | P03956 | 6/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP14 | P50281 | 2/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | FCER2 | P06734 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6687619 | 1.00 | ADAM17 (0.65) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6942867 | 0.83 | ADAM17 (0.68) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6945094 | 0.82 | ADAM17 (0.58) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6942575 | 0.82 | ADAM17 (0.73) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6945099 | 0.82 | ADAM17 (0.58) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6942567 | 0.82 | ADAM17 (0.73) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6945072 | 0.82 | ADAM17 (0.58) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL8097968 | 0.82 | ADAM17 (0.73) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6942562 | 0.82 | ADAM17 (0.73) | ADAM17MMP2MMP3MMP7MMP1 | |
| SCHEMBL6942466 | 0.81 | ADAM17 (0.63) | ADAM17MMP2MMP3MMP7MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004096206-A2 | THERAPEUTIC COMBINATION OF A COX-2 INHIBITOR AND A TACE INHIBITOR | PHARMACIA CORPORATION (US) | 2004-11-11 | — | — | WO | claimed |
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PHARMACIA CORPORATION | 2004-06-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PTGES2, PTGS2, PTGIS | ADAM17 22/4885MMP2 60/4885MMP3 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.